Esperion to Participate in Upcoming September Investor Conferences

Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Upcoming Events - Esperion will participate in the Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET [1] - The company will also attend the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET [1] Webcast Information - Live webcasts of the events can be accessed on the investor and media section of the Esperion website [2] - Replay of the webcasts will be available approximately two hours after the events and archived for about 90 days [2] Strategic Focus - Esperion is advancing its pre-clinical pipeline and focusing on developing ATP citrate lyase inhibitors (ACLYi) [3][4] - The company aims to leverage new insights into the structure and function of ACLYi for rational drug design, targeting the development of highly potent and specific inhibitors [3]